HMPL-306 is under clinical development by Hutchison MediPharma and currently in Phase I for Low-Grade Glioma. According to GlobalData, Phase I drugs for Low-Grade Glioma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the HMPL-306 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HMPL-306 overview
HMPL-306 is under development for the treatment of solid tumors including cholangiocarcinoma, skeletal chondrosarcoma and low-grade glioma. relapsed and refractory myeloid hematological tumors, acute myeloid leukemia, myelodysplastic syndrome or chronic myelomonocytic leukemia, angioimmunoblastic T-cell lymphoma (AITL)/immunoblastic lymphadenopathy, acute myelocytic leukemia, perioperative low-grade glioma and others myeloid neoplasm. The drug candidate is administered by oral route as tablet formulation. It acts by targeting isocitric dehydrogenase 1 and 2. The drug candidate is a new molecular entity (NME).
See Also:
Hutchison MediPharma overview
Hutchison MediPharma (HMPL) carries out discovery, development and commercialization of therapeutics in oncology and autoimmune diseases. The company’s products include savolitinib, fruquintinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. It develops drug discovery technologies in molecular and cell biology, high throughput screening, genomics and informatics to support research and development projects. HMPL’s research and development programs comprise gene-targeted and cell-based screening assays, ligand-dependent screening assays and signal transduction pathway screening assays. The company’s products serve in the fields of medicinal chemistry, pharmacology, oncology, cardiovascular and respiratory diseases, and antiviral treatments. It operates through its two offices in Pudong, China. HMPL is headquartered in Pudong, China.
For a complete picture of HMPL-306’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
